| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer E Van Cutsem, M Peeters, S Siena, Y Humblet, A Hendlisz, B Neyns, ... Journal of clinical oncology 25 (13), 1658-1664, 2007 | 2450 | 2007 |
| Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ... Journal of clinical oncology 36 (8), 773-779, 2018 | 2042 | 2018 |
| Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal … A Hendlisz, MV Eynde, M Peeters, G Maleux, B Lambert, J Vannoote, ... Journal of clinical oncology 28 (23), 3687-3694, 2010 | 508 | 2010 |
| Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors D Strumberg, JW Clark, A Awada, MJ Moore, H Richly, A Hendlisz, ... The oncologist 12 (4), 426-437, 2007 | 490 | 2007 |
| First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study HJ Lenz, E Van Cutsem, M Luisa Limon, KYM Wong, A Hendlisz, ... Journal of clinical oncology 40 (2), 161-170, 2022 | 483 | 2022 |
| Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours A Awada, A Hendlisz, T Gil, S Bartholomeus, M Mano, D de Valeriola, ... British journal of cancer 92 (10), 1855-1861, 2005 | 412 | 2005 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 397 | 2017 |
| Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study R Marechal, B Vos, M Polus, T Delaunoit, M Peeters, P Demetter, ... Annals of oncology 23 (6), 1525-1530, 2012 | 199 | 2012 |
| Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres P Flamen, B Vanderlinden, P Delatte, G Ghanem, L Ameye, ... Physics in Medicine & Biology 53 (22), 6591, 2008 | 176 | 2008 |
| Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study A Demols, M Peeters, M Polus, R Marechal, F Gay, E Monsaert, ... British journal of cancer 94 (4), 481-485, 2006 | 171 | 2006 |
| Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up … T André, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ... Annals of Oncology 33 (10), 1052-1060, 2022 | 162 | 2022 |
| Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study E Van Cutsem, S Tejpar, D Vanbeckevoort, M Peeters, Y Humblet, ... Journal of clinical oncology 30 (23), 2861-2868, 2012 | 157 | 2012 |
| Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab … M Peeters, S Siena, E Van Cutsem, A Sobrero, A Hendlisz, S Cascinu, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2009 | 153 | 2009 |
| Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers H Legendre, C Decaestecker, N Nagy, A Hendlisz, MP Schüring, I Salmon, ... Modern pathology 16 (5), 491-504, 2003 | 152 | 2003 |
| Treatment of colorectal liver metastases: a review MV d Eynde, A Hendlisz Reviews on recent clinical trials 4 (1), 56-62, 2009 | 137 | 2009 |
| Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset H Blons, JF Emile, K Le Malicot, C Julié, A Zaanan, J Tabernero, E Mini, ... Annals of oncology 25 (12), 2378-2385, 2014 | 133 | 2014 |
| Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer A Hamm, H Prenen, W Van Delm, M Di Matteo, M Wenes, E Delamarre, ... Gut 65 (6), 990-1000, 2016 | 107 | 2016 |
| New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel JL Van Laethem, C Verslype, JL Iovanna, P Michl, T Conroy, C Louvet, ... Annals of oncology 23 (3), 570-576, 2012 | 100 | 2012 |
| Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR … HJJ Lenz, E Van Cutsem, ML Limon, KY Wong, A Hendlisz, M Aglietta, ... Annals of oncology 29, viii714, 2018 | 99 | 2018 |
| Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials N Charette, C Vandeputte, L Ameye, CV Bogaert, J Krygier, T Guiot, ... BMC cancer 19, 1-9, 2019 | 94 | 2019 |
Thomas GuiotInstitut Jules BordetGeverifieerd e-mailadres voor bordet.be
